Neuropsychopharmacology
February 13, 2026
Fabrizio Ascone, Valeria Buzzelli, Francesca Mottarlini et al.
2 citations
Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a synaptic disorder, FXS involves the loss of Fragile X messenger ribonucleoprotein 1 (FMRP), leading to abnormal dendrite development and immature dendritic spines. Serotonergic signaling, essential for neuronal development and circuit remodeling,...
Psychopharmacology
November 15, 2025
Elisabetta Ciccocioppo, Sara Massetti, Marcus W. Meinhardt et al.
Alcohol use disorder (AUD) represents a significant medical challenge, with available therapeutic approaches having limited efficacy. Emerging data suggest that psychedelic compounds could represent an alternative treatment for AUD. Among this class of molecules, ketamine, a dissociative psychedelic, shows promising properties. It reduces alcohol drinking in rodents and in humans it is used to...
Neuropharmacology
October 17, 2023
Lucia Caffino, Francesca Mottarlini, Alessandro Piva et al.
14 citations
Despite several decades of investigations, the mechanisms underlying the rapid action of ketamine as antidepressant are still far from being completely understood. Several studies indicated Brain-Derived Neurotrophic Factor (BDNF) as critical for the fast antidepressant action of ketamine, due to its contribution in early and rapid synaptic adaptations. However, previous reports have been...
British Journal of Pharmacology
July 13, 2023
Sabrine Bilel, Erica Zamberletti, Lucia Caffino et al.
Background and purpose: Psychotic disorders have been reported in long-term users of synthetic cannabinoids. This study aims at investigating the long-lasting effects of repeated JWH-018 exposure. Experimental approach: Male CD-1 mice were injected with vehicle, JWH-018 (6 mg·kg-1 ), the CB1 -antagonist NESS-0327 (1 mg·kg-1 ) or co-administration of NESS-0327 and JWH-018, every day for 7 days....